Notably, colorectal cancer happens to be the second most common type of cancer among women globally and the third among men. Colorectal cancer affects the large intestines and the rectum. Cancers are caused by the unusual growth of cells that can easily tamper with other parts of the body. In most cases, colorectal cancer starts as a growth (polyp) on the inner lining of the colon or the rectum. The growth of these abnormal cells may lead to organ failure, which can be fatal to your health. Besides the various treatments options for colorectal cancer available, the BRAFTOVI MEKTOVI is among the newest in the market.
BRAFTOVI MEKTOVI Colorectal Cancer Treatments
BRAFTOVI is an orally-administered minute-molecule that inhibits BRAF Kinase. MEKTOVI is an equally small oral molecule that inhibits the MEK. The two target MAPK major enzymes to signal the RAS-RAF-MEK-ERK pathway. Notably, many types of cancers including colorectal, melanoma, and thyroid among others often experience unusual activation of proteins in this pathway. Good news for patients in the U.S is that BRAFTOVI MEKTOVI is approved for the treatment of metastatic melanoma. The treatment primarily relies on BRAFV600E and BRAFV600k-mutation following the tests approved by the FDA. However, patients with the wild-type of BRAF melanoma are not fit for this treatment.
Patients under the BRAFTOVI MEKTOVI colorectal cancer treatments may experience adverse effects such as diarrhea, abdominal pains, fatigue, nausea, and vomiting. One may also have hyperkeratosis, headaches, impaired vision, and serous retinopathy among others. While using BRAFTOVI, patients are advised to avoid the concomitant use of strong and moderate CYP3A4 inhibitors and inducers. Additionally, sensitive substrates of CYP3A4 should also be avoided during the treatment.
The BRAFTOVI MEKTOVI treatments appear to be the savior to patients with BRAFV600E-mutant metastatic colorectal cancer. The treatment is a combination of three substances: BRAFTOVI, MEKTOVI, and . BRAF mutations are very common among patients suffering from colorectal cancer. Chances of getting the BRAFV600E mutation are higher than getting the BRAF wild-type. As such, the treatment will greatly help these patients in critical need. However, this treatment is only limited to the U.S. while awaiting approval from the FDA; investigations on its effectiveness is still underway.
For excellent results, the patient is advised to see the full prescribing information for both BRAFTOVI and MEKTOVI. Array BioPharma Inc. is responsible for the BRAFTOVI MEKTOVI colorectal cancer treatments in the United States.
Featured Image: depositphotos/Zerbor